In mouse models of HCC, IDO1 blockade along with anti-CTLA-4 treatment proved a more effective means to reduce tumor growth than anti-CTLA-4 monotherapy, paving the way for IDO1 inhibitors to be tested in combination therapies [64]. Here, CTLA4 is linked to hepatocellular carcinoma.